Abstract
Most oncogenes encode activators of transcription factors or transcription factors themselves. Transcription factors that are induced by growth stimuli are, in contrast to transcription factors that regulate house keeping genes, tightly regulated and only active, when a stimulus (e.g. cytokines or other growth factors) is given. Examples of such transcription factors are members of the jun, fos, myc, NFkB and STAT gene families. In cancer cells this regulation is interrupted, resulting in constitutive activities of transcription factors that are normally silent. This in turn results in the increased expression of target genes that are necessary for growth and protection from apoptosis. Since inducible transcription factors are activated by specific pathways, the identification of unusual constitutively active transcription factors also identifies the involved signal transduction pathway. Inhibitors of the components of these pathways may be effective anti-cancer agents, as they interrupt the abnormal signalling and in cancer cells. We applied this strategy for two forms of cutaneous T cell lymphomas and identified several groups of agents that may be the prototypes of new drugs to fight these diseases.
Keywords: Signal transduction, tyrosine kinase inhibitors, apoptosis inducers, skin cancer, sodium salicylate, arsenic trioxide, potassium antimonyl tartrate
Current Drug Discovery Technologies
Title: Transcription Factor Profiling Shows New Ways Towards New Treatment Options of Cutaneous T cell lymphomas
Volume: 4 Issue: 1
Author(s): Udo Dobbeling
Affiliation:
Keywords: Signal transduction, tyrosine kinase inhibitors, apoptosis inducers, skin cancer, sodium salicylate, arsenic trioxide, potassium antimonyl tartrate
Abstract: Most oncogenes encode activators of transcription factors or transcription factors themselves. Transcription factors that are induced by growth stimuli are, in contrast to transcription factors that regulate house keeping genes, tightly regulated and only active, when a stimulus (e.g. cytokines or other growth factors) is given. Examples of such transcription factors are members of the jun, fos, myc, NFkB and STAT gene families. In cancer cells this regulation is interrupted, resulting in constitutive activities of transcription factors that are normally silent. This in turn results in the increased expression of target genes that are necessary for growth and protection from apoptosis. Since inducible transcription factors are activated by specific pathways, the identification of unusual constitutively active transcription factors also identifies the involved signal transduction pathway. Inhibitors of the components of these pathways may be effective anti-cancer agents, as they interrupt the abnormal signalling and in cancer cells. We applied this strategy for two forms of cutaneous T cell lymphomas and identified several groups of agents that may be the prototypes of new drugs to fight these diseases.
Export Options
About this article
Cite this article as:
Udo Dobbeling , Transcription Factor Profiling Shows New Ways Towards New Treatment Options of Cutaneous T cell lymphomas, Current Drug Discovery Technologies 2007; 4 (1) . https://dx.doi.org/10.2174/157016307781115467
DOI https://dx.doi.org/10.2174/157016307781115467 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polyploidy: The Link Between Senescence and Cancer
Current Pharmaceutical Design Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling
Current Gene Therapy Genome and Transcriptome Analysis of Neuroblastoma Advanced Diagnosis from Innovative Therapies
Current Pharmaceutical Design Pomegranate, its Components, and Modern Deliverable Formulations as Potential Botanicals in the Prevention and Treatment of Various Cancers
Current Drug Delivery Machine Learning Based Pattern Recognition Applied to Microarray Data
Combinatorial Chemistry & High Throughput Screening Targeted Alpha Therapy with 227Th-trastuzumab of Intraperitoneal Ovarian Cancer in Nude Mice
Current Radiopharmaceuticals The Role of IL-27 and its Receptor in the Pathogenesis of HIV/AIDS and Anti-viral Immune Response
Current HIV Research MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) Emerging Concepts on Inhibitors of Indoleamine 2,3-Dioxygenase in Rheumatic Diseases
Current Medicinal Chemistry Gallium in Cancer Treatment
Current Topics in Medicinal Chemistry vHTS, 3-D Pharmacophore, QSAR and Molecular Docking Studies for the Identification of Phyto-derived ATP-Competitive Inhibitors of the BCR-ABL Kinase Domain
Current Drug Discovery Technologies Specificity of Binding in Protein Kinases
Current Enzyme Inhibition Co-morbidity of Covid-19 and Stenotrophomonas maltophilia in a Patient with Hodgkin's Lymphoma History from North of Iran
Infectious Disorders - Drug Targets COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases
Current Rheumatology Reviews The Potential for Genetically Altered Microglia to Influence Glioma Treatment
CNS & Neurological Disorders - Drug Targets Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME
Anti-Cancer Agents in Medicinal Chemistry Histone Modifier Differentially Regulates Gene Expression and Unravels Survival Role of MicroRNA-494 in Jurkat Leukemia
MicroRNA Chemical and Genetic Engineering Strategies to Improve the Potency of Pharmaceutical Proteins and Enzymes
Current Medicinal Chemistry Further Perspectives on Diabetes: NeuroRegulation of Blood Glucose
Neuroscience and Biomedical Engineering (Discontinued) Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets